Wildy logo
(020) 7242 5778
enquiries@wildy.com

Wildy’s Book News

Book News cover photo

Vol 21 No 11 Nov/Dec 2016

Book of the Month

Cover of Criminal Injuries Compensation Claims

Criminal Injuries Compensation Claims

Price: £99.95

Pupillage & Student Offers

Special Discounts for Pupils, Newly Called & Students

Read More ...


Secondhand & Out of Print

Browse Secondhand Online

Read More...


Law and the Regulation of Medicines


ISBN13: 9781849461795
Published: March 2012
Publisher: Hart Publishing
Country of Publication: UK
Format: Paperback
Price: £33.99



Low stock.

Also available as
£28.32
+ £5.67 VAT

The principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from the definition of a medicine, through clinical trials, licensing, pharmacovigilance, litigation, marketing and funding.

While the UK's regulatory regime is the principal focus, the question of global access to medicines is addressed not only because of its political importance, but also because it is an issue which places the question of whether medicines are a private or a public good in particularly stark focus.

Two further specific challenges to the future of medicines regulation are examined separately: pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and the possibility of using medicines to enhance wellbeing or performance, rather than treat disease.

Throughout, the emphasis is upon the role of regulation in shaping and influencing the operation of the medicines industry, an issue which is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources.

Subjects:
Medical Law
Contents:
1. What are Medicines and why are they Special?
2. Clinical Trials
3. Licensing
4. Pharmacovigilance and Liability for Dangerous Drugs
5. Marketing
6. Funding and Access to Medicines in the UK
7. Funding and Access to Medicines: A Global Problem
8. The Future of Medicines I Pharmacogenetics
9. The Future of Medicines II: Enhancement
Conclusion